SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-084937
Filing Date
2023-11-09
Accepted
2023-11-09 08:00:41
Documents
67
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0923_cadrenal.htm   iXBRL 10-Q 693354
2 CERTIFICATION f10q0923ex31-1_cadrenal.htm EX-31.1 10968
3 CERTIFICATION f10q0923ex31-2_cadrenal.htm EX-31.2 10666
4 CERTIFICATION f10q0923ex32-1_cadrenal.htm EX-32.1 4737
5 CERTIFICATION f10q0923ex32-2_cadrenal.htm EX-32.2 4530
  Complete submission text file 0001213900-23-084937.txt   4843266

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20230930.xsd EX-101.SCH 52826
7 XBRL CALCULATION FILE cvkd-20230930_cal.xml EX-101.CAL 35047
8 XBRL DEFINITION FILE cvkd-20230930_def.xml EX-101.DEF 247823
9 XBRL LABEL FILE cvkd-20230930_lab.xml EX-101.LAB 486421
10 XBRL PRESENTATION FILE cvkd-20230930_pre.xml EX-101.PRE 264101
61 EXTRACTED XBRL INSTANCE DOCUMENT f10q0923_cadrenal_htm.xml XML 548270
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41596 | Film No.: 231390135
SIC: 2834 Pharmaceutical Preparations